Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (LCTX)
:LCTX
LCTX Stock Chart & Stats
$1.70
-$0.04(-6.64%)
At close: 4:00 PM EST
$1.70
-$0.04(-6.64%)
Day’s Range― - ―
52-Week Range$0.37 - $2.09
Previous CloseN/A
Volume522.43K
Average Volume (3M)1.09M
Market Cap
$391.56M
Enterprise Value$347.65M
Total Cash (Recent Filing)$40.49M
Total Debt (Recent Filing)$2.62M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Mar 05, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding230,327,530
10 Day Avg. Volume1,011,212
30 Day Avg. Volume1,090,985
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.28
Price to Sales (P/S)10.59
P/FCF Ratio-4.25
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue32.14
Enterprise Value/Gross Profit32.85
Enterprise Value/Ebitda-7.62
Forecast
1Y Price Target
$4.50Price Target Upside164.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Safety DataAnalyst cites reported vision improvements for OpRegen and the DOSED study's favorable interim safety observations as clinical signals that could bolster investor confidence and aid regulatory discussions.
Manufacturing And ScalabilityAnalyst notes the acquisition of a gene-edited hypoimmune cell line plus successful scalable GMP manufacturing and integration with the AlloSCOPE platform strengthens capacity to produce off-the-shelf cell therapies and accelerate program advancement.
Partner Commitment And MilestoneAnalyst highlights Roche's milestone payment and active testing of next-generation delivery devices as signs of strong partner commitment that could reduce development risk for OpRegen and support future commercialization prospects.
Bears Say
Accounting-driven Financial PressureAnalyst flags a wider-than-expected loss driven by warrant liability accounting as a factor that may pressure reported results and investor perception until accounting impacts are clarified.
Data Transparency RiskAnalyst warns that limited visibility into clinical data from the global partner creates uncertainty around program timing and the likelihood of success, which could dampen market sentiment.
Lineage Therap News
LCTX FAQ
What was Lineage Cell Therapeutics, Inc.’s price range in the past 12 months?
Lineage Cell Therapeutics, Inc. lowest stock price was $0.36 and its highest was $2.09 in the past 12 months.
What is Lineage Cell Therapeutics, Inc.’s market cap?
Lineage Cell Therapeutics, Inc.’s market cap is $391.56M.
When is Lineage Cell Therapeutics, Inc.’s upcoming earnings report date?
Lineage Cell Therapeutics, Inc.’s upcoming earnings report date is Mar 05, 2026 which is in 48 days.
How were Lineage Cell Therapeutics, Inc.’s earnings last quarter?
Lineage Cell Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.026 by -$0.104.
Is Lineage Cell Therapeutics, Inc. overvalued?
According to Wall Street analysts Lineage Cell Therapeutics, Inc.’s price is currently Undervalued.
Does Lineage Cell Therapeutics, Inc. pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
What is Lineage Cell Therapeutics, Inc.’s EPS estimate?
Lineage Cell Therapeutics, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Lineage Cell Therapeutics, Inc. have?
Lineage Cell Therapeutics, Inc. has 230,327,530 shares outstanding.
What happened to Lineage Cell Therapeutics, Inc.’s price movement after its last earnings report?
Lineage Cell Therapeutics, Inc. reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.026. Following the earnings report the stock price went up 1.734%.
Which hedge fund is a major shareholder of Lineage Cell Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LCTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lineage Therap Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (164.71% Upside)
$4.50 (164.71% Upside)
Blogger Sentiment
Bullish
LCTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
179.26%
12-Months-Change
Fundamentals
Return on Equity
-153.37%
Trailing 12-Months
Asset Growth
-7.20%
Trailing 12-Months
Company Description
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
LCTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While Lineage has made significant progress with its OpRegen program and secured important partnerships, financial challenges persist with a decrease in revenue and a significant net loss. The advancements in clinical trials and partnerships offer promising long-term potential, but financial metrics present short-term challenges.View all LCTX earnings summariesLCTX Stock 12 Month Forecast
Average Price Target
$4.50
▲(164.71% Upside)
Technical Analysis
Amarin
―
Tvardi Therapeutics
―
DBV Technologies SA - American
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―
Ownership Overview
58.19% Insiders
4.66% Mutual Funds
0.02% Other Institutional Investors
32.72% Public Companies and
Individual Investors